OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+47.65%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$600M
AUM Growth
+$600M
(+37%)
Cap. Flow
+$6.02M
Cap. Flow
% of AUM
1%
Top 10 Holdings %
Top 10 Hldgs %
72.6%
Holding
57
New
6
Increased
11
Reduced
18
Closed
13
Top Buys
| 1 |
Arvinas
ARVN
|
$17.2M |
| 2 |
Codexis
CDXS
|
$16.4M |
| 3 |
Liquidia Corp
LQDA
|
$13.7M |
| 4 |
Ginkgo Bioworks
DNA
|
$6.68M |
| 5 |
Zentalis Pharmaceuticals
ZNTL
|
$3.56M |
Top Sells
| 1 |
Catalyst Pharmaceutical
CPRX
|
$10.5M |
| 2 |
4D Molecular Therapeutics
FDMT
|
$7.26M |
| 3 |
Iovance Biotherapeutics
IOVA
|
$7.19M |
| 4 |
Cytokinetics
CYTK
|
$6.5M |
| 5 |
Intellia Therapeutics
NTLA
|
$4.88M |
Sector Composition
| 1 | Healthcare | 98.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Harrow
HROW
$1.44B
| $179M | 29.92% | 3,990,000 | – | – |
|
2
TG Therapeutics
TGTX
$4.65B
| $53.3M | 8.89% | 2,280,000 | – | – |
|
3
Ocular Therapeutix
OCUL
$2.12B
| $43.7M | 7.29% | 5,025,000 -282,500 | -5% | -$2.46M |
|
|
4
Arvinas
ARVN
$568M
| $30.9M | 5.16% | 1,255,000 +700,000 | +126% | +$17.2M |
|
|
5
Codexis
CDXS
$246M
| $27M | 4.51% | 8,770,000 +5,315,000 | +154% | +$16.4M |
|
6
Rhythm Pharmaceuticals
RYTM
$6.85B
| $26.2M | 4.37% | 500,000 -15,000 | -3% | -$786K |
|
7
Keros Therapeutics
KROS
$618M
| $23M | 3.83% | 395,276 +27,776 | +8% | +$1.61M |
|
8
Immunome
IMNM
$828M
| $18.1M | 3.02% | 1,237,500 +135,000 | +12% | +$1.97M |
|
|
9
Liquidia Corp
LQDA
$2.38B
| $17M | 2.83% | 1,698,142 +1,373,142 | +423% | +$13.7M |
|
10
Eton Pharmaceutcials
ETON
$464M
| $16.7M | 2.78% | 2,780,000 +385,000 | +16% | +$2.31M |
|
11
Edgewise Therapeutics
EWTX
$1.51B
| $13.9M | 2.33% | 522,500 -57,500 | -10% | -$1.53M |
|
|
CRGX
12
DELISTED
CARGO Therapeutics
CRGX
| $11.8M | 1.97% | 541,437 -14,263 | -3% | -$312K |
|
13
Applied Therapeutics
APLT
$71M
| $11.2M | 1.87% | 1,320,000 -360,000 | -21% | -$3.06M |
|
14
Vaxcyte
PCVX
$4B
| $9.71M | 1.62% | 85,000 | – | – |
|
15
Nurix Therapeutics
NRIX
$714M
| $9.44M | 1.57% | 420,000 +1,072 | +0.3% | +$24.1K |
|
|
SLRN
16
DELISTED
ACELYRIN
SLRN
| $9.34M | 1.56% | 1,893,660 +313,660 | +20% | +$1.55M |
|
17
Trevi Therapeutics
TRVI
$883M
| $8.58M | 1.43% | 2,567,990 -77,010 | -3% | -$257K |
|
18
Biodesix
BDSX
$62.6M
| $6.97M | 1.16% | 3,815,000 -205,000 | -5% | -$375K |
|
|
19
Ginkgo Bioworks
DNA
$750M
| $6.68M | 1.11% | +820,202 | New | +$6.68M |
|
20
Jasper Therapeutics
JSPR
$45.5M
| $6.65M | 1.11% | 353,500 -38,500 | -10% | -$724K |
|
21
Xoma
XOMA
$392M
| $6.62M | 1.1% | 250,000 | – | – |
|
22
Nuvalent
NUVL
$5.52B
| $6.55M | 1.09% | 64,000 +4,700 | +8% | +$481K |
|
23
NewAmsterdam Pharma
NAMS
$2.71B
| $5.56M | 0.93% | 335,000 +20,000 | +6% | +$332K |
|
24
UroGen Pharma
URGN
$900M
| $5.13M | 0.86% | 404,100 -7,900 | -2% | -$100K |
|
25
Protagonist Therapeutics
PTGX
$3.67B
| $4.73M | 0.79% | 105,000 | – | – |
|